Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16058499 | 0.91 | PTGS1 (0.48) | PTGS1SLC7A11SLC1A5IDO1NOS3 | |
| SCHEMBL18152975 | 0.88 | SLC1A5 (0.37) | PTGS1SLC7A11SLC1A5IDO1NOS3 | |
| SCHEMBL4851690 | 0.86 | PTGS1 (0.39) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| Glycine SCHEMBL12500492 | 0.86 | SLC1A5 (0.36) | PTGS1SLC7A11SLC1A5IDO1NOS3 | |
| Cysteine SCHEMBL2597897 | 0.86 | PTGS1 (0.59) | PTGS1SLC7A11SLC1A5IDO1NOS3 | |
| SCHEMBL5272389 | 0.85 | SLC1A5 (0.33) | SLC1A5IDO1NOS3NOS1NOS2 | |
| Serine SCHEMBL5271395 | 0.85 | SLC1A5 (0.34) | SLC1A5IDO1 | |
| SCHEMBL17113866 | 0.84 | PTGS1 (0.60) | PTGS1SLC7A11SLC1A5IDO1NOS3 | |
| SCHEMBL8074429 | 0.83 | PTGS1 (0.39) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL4752999 | 0.82 | SLC1A5 (0.40) | PTGS1SLC7A11SLC1A5IDO1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236510-B2 | Protein showing enhanced expression in cancer cells | AGENSYS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100291126-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | AGENSYS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7795391-B2 | Protein showing enhanced expression in cancer cells | AGENSYS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7361338-B2 | Methods to inhibit growth of prostate cancer cells | AGENSYS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070270575-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | AGENSYS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070061901-A9 | METHODS TO INHIBIT GROWTH OF PROSTATE CANCER CELLS | JAKOBOVITS AYA | 2007-03-15 | — | — | US | disclosed |
| US-20030213004-A1 | Nucleic acids and corresponding proteins entitled 101P3A11 or PHOR-1 useful in treatment and detection of cancer | AGENSYS, INC. | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291126-A1 | PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS | TSG101, BCAP31, TFIP11 | PTGS1 3780/4885SLC7A11 3432/4885SLC1A5 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.